Posts Tagged: drug pricing


Bankrupting Big Pharma Isn’t a Solution

Believe it or not, a recent op-ed in the Washington Post written by Robin Feldman took the position that pharmaceutical companies should charge prices for their drugs …
By Gene Quinn
1 month ago 56

Senate Judiciary Committee Advances Legislation to Reduce Drug Prices, Rein in Pharma Industry Practices

Earlier today, the Senate Judiciary Committee held an Executive Business Meeting in which the Committee discussed and favorably reported four bills aimed at reducing prescription drug prices …
By Eileen McDermott
2 months ago 2

House Committee Targets AbbVie Patent Practices, Urges FTC to Investigate

Yesterday, Representatives Carolyn Maloney (D-NY), Jerrold Nadler (D-NY) and David Cicilline (D-RI) asked Federal Trade Commission (FTC) Acting Chair Rebecca Kelly Slaughter to open a formal inquiry …
By Eileen McDermott
4 months ago 7

Bills to Lower Prescription Drug Costs and Boost Biosimilars Sent to Biden’s Desk

The U.S. House of Representatives yesterday approved two bills meant to lower prescription drug prices and sent them on to President Joe Biden for approval. The …
By Eileen McDermott
5 months ago 1

Industry Comments on Proposed Changes to Bayh-Dole Regulations Zero in on March-In Language

On January 12, the National Institute of Standards and Technology (NIST) published a request for comments on proposed changes to regulations that support the University and Small Business …
By Gene Quinn
5 months ago 0

No, You Can’t March in On Remdesivir

One thing you should never say in 2020 is: "Well, at least things can't get any worse." They can and often do. The latest exhibit—in the intellectual …
By Joseph Allen
1 year ago 5

Medical Innovation Depends on Bayh-Dole’s IP Protections

In this age of polarization, it’s almost impossible to imagine Congress enacting bipartisan legislation that would benefit businesses, higher education, and consumers alike. But that is …
By Steven Tepp
2 years ago 4

Severing the Link Between IP and Biomedical Innovation Isn’t the Answer to Global Health Care Challenges

The cost of medicines is on the agenda this week at the World Health Organization’s annual executive board meeting in Geneva. Nongovernmental organizations and certain middle-income …

Responding to Criticism of ‘State Pharmaceutical Importation Programs Threaten Patients and Innovation’

A recent article by Dr. Kristina M. L. Acri née Lybecker highlighted her research about the fiscal workability of state pharmaceutical importation programs from two important …
By Shabbir Imber-Safdar
2 years ago 22

State Pharmaceutical Importation Programs Threaten Patients and Innovation

In mid-December, President Trump presented a plan to lower prescription drug prices by allowing states, drug wholesalers and pharmacies to import some cheaper drugs from Canada. While …

Will Bayh-Dole Survive Its 40th Birthday?

Next year marks the 40th anniversary of the passage of the Bayh-Dole Act. With election day looming, 2020 is likely to be the most politically contentious year of …
By Joseph Allen
2 years ago 1

As Lighthizer Negotiates on USMCA, Former HHS Secretary Warns Against Buying Into ‘Myths’

On September 13, U.S. Trade Representative Robert Lighthizer reportedly expressed a willingness to negotiate on several points of contention regarding the U.S.-Mexico-Canada Agreement (USMCA), including …
By IPWatchdog
2 years ago 0

Don’t Ignore the Flashing Caution Lights in the Drug Pricing Debate

Trying to rationally address hot button issues in an election year is always a dangerous proposition. That's particularly true as we approach what promises to be one …
By Joseph Allen
2 years ago 1

Other Barks & Bites for Friday, July 12: Final Rule on Drug Prices in TV Ads Blocked, Huawei Pronounced Top Chinese Patent Earner, and Brazil Joins Madrid Agreement

This week in Other Barks & Bites: The Trump Administration’s Final Rule that would have required list prices of drugs to be displayed in television ads is …
By IPWatchdog
2 years ago 0

Amidst Push for a Summer Vote on USMCA, Report Argues RDP Requirement Would Not Raise Drug Prices

In the face of pressure to pull provisions in the United States-Mexico-Canada Agreement (USMCA) that would grant 10 years of regulatory data protection (RDP) for biologics inventions, a …
By Eileen McDermott
2 years ago 0